ReviewHormones (Athens, Greece)2026
Endocrine disruptors are contributing to type 2 diabetes mellitus.
Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of type 2 diabetes mellitus (T2DM) is rising exponentially, with alarming projections from the International Diabetes Federation estimating 589 million affected individuals in 2024 and more than 850 million in 2050. This represents an economic burden of approximately €1,015 billion worldwide. Traditional explanations such as sedentary lifestyle and overeating are insufficient to explain such a rapid expansion of the disease. Increasing attention has therefore turned toward the role of environmental endocrine disruptors (EDs), and, in particular, of persistent organic pollutants (POPs).EDs are natural or synthetic molecules capable of altering endocrine function by interfering with biochemical pathways. They are omnipresent in daily life and have for several decades been implicated in reproductive or thyroid disorders, various hormone-dependent cancers (breast, prostate, testicular and colon cancers) and metabolic complications such as obesity.To better understand their diabetogenic potential, numerous experimental studies have been conducted. In vitro findings showed that certain POPs increase insulin resistance in cultured adipocytes or myocytes. Bisphenol A, widely used in plastic manufacturing, induces an initial hypersecretion of insulin in pancreatic islets, followed by a later decrease in insulin sensitivity. In vivo animal studies similarly demonstrate strong diabetogenic effects.In humans, epidemiological and longitudinal studies have revealed direct associations between exposure to POPs (e.g., organochlorine pesticides, dioxins, and polychlorinated biphenyls) and the onset of metabolic syndrome or T2DM. These effects were first observed after acute environmental exposure, such as the Seveso disaster. More recent large-scale studies confirm higher circulating levels of EDs in people living with obesity and/or T2DM, strongly demonstrating that these compounds are independent risk factors for insulin resistance.Collectively, the evidence now supports a central role of EDs in the global rise of obesity and T2DM. Their contribution to the epidemic is no longer speculative but increasingly recognized as scientifically established.
Indexed as
Identifiers
42024226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.